U.S. health officials have asked three advanced biology laboratories to submit plans for producing the experimental Ebola drug ZMapp, which ran out after it was given to a handful of medical workers who contracted the disease in West Africa, government and lab officials said on Friday.

Under the "task order" issued on Thursday by the Biomedical Advanced Research and Development Authority (BARDA), a state-of-the-art manufacturing center in Texas will submit plans for manufacturing ZMapp, said Dr. Brett Giroir, chief executive officer of Texas A&M Health Science Center, which houses the lab. The lab works in conjunction with Britain's GlaxoSmithKline.

Read More Every US Ebola patient received experimental product, official says



One of three Centers for Innovation in Advanced Development and Manufacturing established by U.S. health officials in 2012 with $440 million in seed money, the Texas lab "is swiftly responding" to the request, Giroir said in a statement, and will submit detailed proposals for scaling up production of ZMapp.